Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 229)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 390.080
Gesamt: 390.080
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
6,7700
USD
-4,24 %
-0,3000 USD
Letzter Kurs 18.05.24 NYSE
Neuigkeiten
17.05.24 · Accesswire  |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9300 | -17,52 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Könnte charttechnisch eine interessante Woche werden. Im daily Chart steht ein Golden Cross an
(stand Freitag: SMA50=$14,63, SMA200=$14,77) Und im weekly Chart überschneidet der MACD die Nulllinie diese Woche in den positiven Bereich, dort war er seit über 2 Jahren nicht mehr.
Gruß
(stand Freitag: SMA50=$14,63, SMA200=$14,77) Und im weekly Chart überschneidet der MACD die Nulllinie diese Woche in den positiven Bereich, dort war er seit über 2 Jahren nicht mehr.
Gruß
Antwort auf Beitrag Nr.: 55.378.820 von marty44 am 23.07.17 10:45:44
Institutional investors currently hold around $3.12 billion or 66.8% in VRX stock. Look at its top three institutional owners. Paulson & Co. Inc. owns $339.23 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.55% of the company’s market cap and approximately 10.89% of the institutional ownership. Similar statistics are true for the second largest owner, Valueact Holdings, L.P., which owns 17,997,224 shares of the stock are valued at $314.95 million. The third largest holder is Toronto Dominion Bank, which currently holds $209.31 million worth of this stock and that ownership represents nearly 3.43% of its market capitalization.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Valeant Pharmaceuticals International, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director DE SCHUTTER RICHARD U has acquired 20,000 shares of Valeant Pharmaceuticals International, Inc. (VRX) in trading session dated May. 11, 2017. These shares are worth $278,000 and were traded at $13.9 each. The SEC filing shows that DE SCHUTTER RICHARD U performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Mar. 15, 2017. The company’s shares were assimilated at $10.8 per share worth to an investment of some $108,000 on account of DE SCHUTTER RICHARD U.
EVP and CFO, Herendeen Paul, purchased 24,000 common shares of Valeant Pharmaceuticals International, Inc. (VRX) in the open market. In a transaction dated Mar. 14, 2017, the shares were bought at an average price of $10.72, giving away a sum of $257,280. After this purchase, 174,000 common shares of VRX are directly owned by the insider, with total stake valued at $3,045,000.
In the transaction dated Mar. 14, 2017, the great number of shares acquired came courtesy the ; ValueAct Capital Master Fund, added a total of 3,000,000 shares at an average price of $10.82, amounting to approximately $32,460,000. The insider now directly owns 1,059,793 shares worth $18,546,378.
Valeant Pharmaceuticals International, Inc. (VRX) Top Holders
Valeant Pharmaceuticals International, Inc. (VRX) Top HoldersInstitutional investors currently hold around $3.12 billion or 66.8% in VRX stock. Look at its top three institutional owners. Paulson & Co. Inc. owns $339.23 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.55% of the company’s market cap and approximately 10.89% of the institutional ownership. Similar statistics are true for the second largest owner, Valueact Holdings, L.P., which owns 17,997,224 shares of the stock are valued at $314.95 million. The third largest holder is Toronto Dominion Bank, which currently holds $209.31 million worth of this stock and that ownership represents nearly 3.43% of its market capitalization.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Valeant Pharmaceuticals International, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director DE SCHUTTER RICHARD U has acquired 20,000 shares of Valeant Pharmaceuticals International, Inc. (VRX) in trading session dated May. 11, 2017. These shares are worth $278,000 and were traded at $13.9 each. The SEC filing shows that DE SCHUTTER RICHARD U performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Mar. 15, 2017. The company’s shares were assimilated at $10.8 per share worth to an investment of some $108,000 on account of DE SCHUTTER RICHARD U.
EVP and CFO, Herendeen Paul, purchased 24,000 common shares of Valeant Pharmaceuticals International, Inc. (VRX) in the open market. In a transaction dated Mar. 14, 2017, the shares were bought at an average price of $10.72, giving away a sum of $257,280. After this purchase, 174,000 common shares of VRX are directly owned by the insider, with total stake valued at $3,045,000.
In the transaction dated Mar. 14, 2017, the great number of shares acquired came courtesy the ; ValueAct Capital Master Fund, added a total of 3,000,000 shares at an average price of $10.82, amounting to approximately $32,460,000. The insider now directly owns 1,059,793 shares worth $18,546,378.
Von Stocktwits, für die die es verstehen mögen.
Mir reicht das Fazit.
Mir reicht das Fazit.
Antwort auf Beitrag Nr.: 55.376.021 von marty44 am 22.07.17 10:50:55Danke!
chicko
chicko
Antwort auf Beitrag Nr.: 55.375.631 von chicko6 am 22.07.17 09:16:49
google kaputt?
http://ir.valeant.com/events-and-presentations/2017
Zitat von chicko6: hallo!
Weis jemand wann die Q2 Zahlen präsentiert werden?
Danke
chicko
google kaputt?
http://ir.valeant.com/events-and-presentations/2017
Trading Spotlight
hallo!
Weis jemand wann die Q2 Zahlen präsentiert werden?
Danke
chicko
Weis jemand wann die Q2 Zahlen präsentiert werden?
Danke
chicko
Nur für das Umfeld:
https://www.wallstreet-online.de/nachricht/9762155-biotech-r…
https://www.wallstreet-online.de/nachricht/9762155-biotech-r…
Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Back From the Abyss
http://investorplace.com/2017/07/valeant-pharmaceuticals-int… Sequoia Fund Seen Bouncing Back After Valeant Saga
https://www.gurufocus.com/news/543435/sequoia-fund-seen-boun…Und die Moral von der Geschicht:
Auf tolle Fond-Manager können irren?
Three Lessons from Ackman’s Wager on Valeant
http://themarketmogul.com/valeant-ackman-saga/?hvid=53d0bCDie wesentliche Lektion ist aber doch eher die:
Der EK zählt auch?
Durchsuchen
Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
